Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the first patient has been dosed in the Phase I/II clinical trial of its ...
ClearVue Technologies (ASX:CPV) has secured $881,000 in an Australian government R&D tax rebate, consequently repaying its ...
Sino Biopharmaceutical ( (HK:1177)) has shared an update. Sino Biopharmaceutical Limited announced that its innovative drug, LM-350 ‘CDH17 ADC’, has received clinical trial approval from China’s ...
Final Phase 1b results presented at World Lung Conference highlight the potential of firmonertinib to address unmet needs in EGFR PACC mutant NSCLC Received FDA IND clearance for ARR-217, a CDH-17 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback